Merck Serono, a division of Merck KGaA, Darmstadt,
Germany, announced today that Merck, has signed a worldwide research and
development agreement with sanofi-aventis U.S. Inc., under which Merck Serono
and sanofi-aventis U.S. Inc. will collaboratively investigate novel
experimental combinations of agents that could block specific pathways in
cancer cells. This collaboration could deliver novel targeted oncology treatments
with high therapeutic potential.
The novel combinations involve Merck Serono’s MEK inhibitor MSC1936369B
(also known as AS703026), sanofi-aventis PI3K/mTOR inhibitor SAR245409 (also
known as XL765) and class I PI3K inhibitor SAR245408 (also known as XL147),
respectively.
Under the terms of this agreement, each party will be
initially responsible for conducting a Phase I dose escalation study of these product
candidates. Sanofi-aventis will be granted a research and development license
to MSC1936369B to assess safety and initial clinical activity in combination
with its PI3K inhibitor SAR245408. In conjunction, Merck Serono will be granted
a research and development license to SAR245409 in order to assess safety and
initial clinical activity in combination with its MEK inhibitor MSC1936369B.
“In the spirit of personalizing and stratifying cancer
care, it is a logical step to combine new exciting molecules across pipelines
and companies early on, to explore combined activity against cancer pathways,”
said Dr. Wolfgang Wein, Executive Vice President for Oncology at Merck Serono.
“We expect a strong synergy between both oncology units in driving the
projects forward.” “This collaboration reinforces our commitment to
maximize our portfolio and to provide better treatments for patients with
cancer” said Debasish Roychowdhury, M.D., Senior Vice President, Head of Global
Oncology, sanofi-aventis. “Combining these two promising molecules makes
eminent sense and we are excited to partner with Merck Serono.”
